Adaptive Cash Per Share vs Price To Sales Ratio Analysis

ADPT Stock

USD 3.01 0.08 2.73%

Adaptive Biotechnologies financial indicator trend analysis is way more than just evaluating Adaptive Biotechnologies prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Adaptive Biotechnologies is a good investment. Please check the relationship between Adaptive Biotechnologies Cash Per Share and its Price To Sales Ratio accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptive Biotechnologies Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

Cash Per Share vs Price To Sales Ratio

Cash Per Share vs Price To Sales Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Adaptive Biotechnologies Cash Per Share account and Price To Sales Ratio. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Adaptive Biotechnologies' Cash Per Share and Price To Sales Ratio is -0.53. Overlapping area represents the amount of variation of Cash Per Share that can explain the historical movement of Price To Sales Ratio in the same time period over historical financial statements of Adaptive Biotechnologies Corp, assuming nothing else is changed. The correlation between historical values of Adaptive Biotechnologies' Cash Per Share and Price To Sales Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash Per Share of Adaptive Biotechnologies Corp are associated (or correlated) with its Price To Sales Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price To Sales Ratio has no effect on the direction of Cash Per Share i.e., Adaptive Biotechnologies' Cash Per Share and Price To Sales Ratio go up and down completely randomly.

Correlation Coefficient

-0.53

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Cash Per Share

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Adaptive Biotechnologies stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Adaptive Biotechnologies sales, a figure that is much harder to manipulate than other Adaptive Biotechnologies Corp multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company’s stock price to its revenues, calculated by dividing the company’s market cap by its total sales or revenue over a 12-month period.

Most indicators from Adaptive Biotechnologies' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Adaptive Biotechnologies current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptive Biotechnologies Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

Selling General Administrative is likely to drop to about 57.1 M in 2024. Sales General And Administrative To Revenue is likely to drop to 0.35 in 2024

	2021	2022	2023	2024 (projected)
Gross Profit	105.0M	127.4M	72.5M	78.9M
Total Revenue	154.3M	185.3M	170.3M	123.7M

Gross Profit Total Revenue

Adaptive Biotechnologies fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Inventory
Total Assets		0.89	0.95	0.99	0.87	0.97	0.89	0.98	0.52	-0.64	0.61	0.69	0.9	0.62	0.49	-0.37	0.95	0.56	-0.27	0.92	0.44	0.93	0.92	-0.95	0.89	0.86
Other Current Liab	0.89		0.98	0.91	0.83	0.92	0.99	0.93	0.69	-0.84	0.8	0.51	0.85	0.52	0.2	-0.47	0.8	0.8	-0.36	0.95	0.75	0.79	0.92	-0.93	0.96	0.96
Total Current Liabilities	0.95	0.98		0.97	0.88	0.97	0.98	0.98	0.64	-0.8	0.76	0.6	0.91	0.57	0.36	-0.45	0.86	0.75	-0.34	0.97	0.64	0.84	0.96	-0.98	0.97	0.96
Total Stockholder Equity	0.99	0.91	0.97		0.9	0.99	0.9	0.99	0.54	-0.67	0.66	0.66	0.91	0.61	0.51	-0.38	0.94	0.61	-0.27	0.95	0.45	0.91	0.94	-0.97	0.93	0.88
Other Liab	0.87	0.83	0.88	0.9		0.93	0.79	0.86	0.66	-0.74	0.85	0.3	0.67	0.45	0.64	-0.47	0.88	0.77	-0.36	0.94	0.36	0.9	0.93	-0.92	0.92	0.76
Net Tangible Assets	0.97	0.92	0.97	0.99	0.93		0.91	0.98	0.61	-0.72	0.72	0.59	0.89	0.55	0.5	-0.42	0.91	0.67	-0.31	0.98	0.5	0.9	0.96	-0.98	0.96	0.9
Property Plant And Equipment Net	0.89	0.99	0.98	0.9	0.79	0.91		0.94	0.65	-0.82	0.75	0.59	0.9	0.55	0.18	-0.43	0.76	0.77	-0.32	0.94	0.76	0.73	0.9	-0.93	0.95	0.97
Current Deferred Revenue	0.98	0.93	0.98	0.99	0.86	0.98	0.94		0.56	-0.71	0.66	0.69	0.95	0.61	0.44	-0.39	0.88	0.64	-0.28	0.95	0.53	0.85	0.94	-0.98	0.93	0.93
Net Debt	0.52	0.69	0.64	0.54	0.66	0.61	0.65	0.56		-0.95	0.77	0.05	0.45	-0.21	0.11	-0.93	0.46	0.77	-0.88	0.7	0.67	0.49	0.78	-0.69	0.72	0.68
Retained Earnings	-0.64	-0.84	-0.8	-0.67	-0.74	-0.72	-0.82	-0.71	-0.95		-0.87	-0.2	-0.61	-0.06	-0.12	0.8	-0.54	-0.9	0.74	-0.82	-0.78	-0.55	-0.86	0.8	-0.85	-0.82
Accounts Payable	0.61	0.8	0.76	0.66	0.85	0.72	0.75	0.66	0.77	-0.87		0.03	0.45	0.29	0.32	-0.53	0.6	0.98	-0.45	0.83	0.58	0.64	0.81	-0.76	0.85	0.7
Cash	0.69	0.51	0.6	0.66	0.3	0.59	0.59	0.69	0.05	-0.2	0.03		0.82	0.54	0.16	-0.04	0.56	0.04	0.0	0.48	0.29	0.47	0.48	-0.57	0.45	0.56
Non Current Assets Total	0.9	0.85	0.91	0.91	0.67	0.89	0.9	0.95	0.45	-0.61	0.45	0.82		0.57	0.31	-0.33	0.74	0.47	-0.23	0.84	0.54	0.68	0.83	-0.9	0.82	0.92
Non Currrent Assets Other	0.62	0.52	0.57	0.61	0.45	0.55	0.55	0.61	-0.21	-0.06	0.29	0.54	0.57		0.38	0.39	0.6	0.25	0.49	0.48	0.09	0.57	0.38	-0.48	0.46	0.46
Other Assets	0.49	0.2	0.36	0.51	0.64	0.5	0.18	0.44	0.11	-0.12	0.32	0.16	0.31	0.38		-0.13	0.57	0.17	-0.06	0.43	-0.45	0.59	0.48	-0.49	0.36	0.19
Long Term Debt	-0.37	-0.47	-0.45	-0.38	-0.47	-0.42	-0.43	-0.39	-0.93	0.8	-0.53	-0.04	-0.33	0.39	-0.13		-0.33	-0.52	0.99	-0.49	-0.46	-0.35	-0.64	0.53	-0.49	-0.49
Cash And Short Term Investments	0.95	0.8	0.86	0.94	0.88	0.91	0.76	0.88	0.46	-0.54	0.6	0.56	0.74	0.6	0.57	-0.33		0.5	-0.23	0.85	0.29	0.99	0.85	-0.86	0.81	0.7
Net Receivables	0.56	0.8	0.75	0.61	0.77	0.67	0.77	0.64	0.77	-0.9	0.98	0.04	0.47	0.25	0.17	-0.52	0.5		-0.45	0.8	0.7	0.53	0.77	-0.73	0.84	0.73
Good Will	-0.27	-0.36	-0.34	-0.27	-0.36	-0.31	-0.32	-0.28	-0.88	0.74	-0.45	0.0	-0.23	0.49	-0.06	0.99	-0.23	-0.45		-0.37	-0.42	-0.25	-0.54	0.42	-0.38	-0.37
Common Stock Total Equity	0.92	0.95	0.97	0.95	0.94	0.98	0.94	0.95	0.7	-0.82	0.83	0.48	0.84	0.48	0.43	-0.49	0.85	0.8	-0.37		0.59	0.84	0.97	-0.98	1.0	0.92
Common Stock Shares Outstanding	0.44	0.75	0.64	0.45	0.36	0.5	0.76	0.53	0.67	-0.78	0.58	0.29	0.54	0.09	-0.45	-0.46	0.29	0.7	-0.42	0.59		0.27	0.55	-0.54	0.66	0.74
Short Term Investments	0.93	0.79	0.84	0.91	0.9	0.9	0.73	0.85	0.49	-0.55	0.64	0.47	0.68	0.57	0.59	-0.35	0.99	0.53	-0.25	0.84	0.27		0.85	-0.84	0.8	0.67
Long Term Debt Total	0.92	0.92	0.96	0.94	0.93	0.96	0.9	0.94	0.78	-0.86	0.81	0.48	0.83	0.38	0.48	-0.64	0.85	0.77	-0.54	0.97	0.55	0.85		-0.99	0.96	0.9
Non Current Liabilities Total	-0.95	-0.93	-0.98	-0.97	-0.92	-0.98	-0.93	-0.98	-0.69	0.8	-0.76	-0.57	-0.9	-0.48	-0.49	0.53	-0.86	-0.73	0.42	-0.98	-0.54	-0.84	-0.99		-0.97	-0.93
Capital Surpluse	0.89	0.96	0.97	0.93	0.92	0.96	0.95	0.93	0.72	-0.85	0.85	0.45	0.82	0.46	0.36	-0.49	0.81	0.84	-0.38	1.0	0.66	0.8	0.96	-0.97		0.93
Inventory	0.86	0.96	0.96	0.88	0.76	0.9	0.97	0.93	0.68	-0.82	0.7	0.56	0.92	0.46	0.19	-0.49	0.7	0.73	-0.37	0.92	0.74	0.67	0.9	-0.93	0.93

Click cells to compare fundamentals

Adaptive Biotechnologies Account Relationship Matchups

Adaptive Biotechnologies fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	912.3M	1.1B	923.3M	856.6M	661.1M	811.6M
Other Current Liab	12.9M	25.1M	25.0M	28.4M	22.3M	19.9M
Total Current Liabilities	78.3M	105.2M	113.8M	109.8M	88.0M	84.7M
Total Stockholder Equity	571.0M	743.3M	604.0M	464.2M	308.4M	347.0M
Other Liab	226.3M	163.6M	98.8M	184.0M	211.6M	125.4M
Net Tangible Assets	440.1M	614.1M	476.5M	338.4M	389.1M	205.2M
Property Plant And Equipment Net	60.4M	139.0M	172.9M	164.2M	120.3M	108.4M
Current Deferred Revenue	61.0M	73.3M	80.5M	64.1M	48.6M	55.7M
Net Debt	(60.0M)	(15.6M)	(27.3M)	18.0M	164.4M	172.6M
Retained Earnings	(365.5M)	(511.6M)	(718.9M)	(919.1M)	(1.1B)	(1.1B)
Accounts Payable	4.5M	3.2M	3.3M	8.1M	7.7M	4.8M
Cash	96.6M	123.4M	139.1M	90.0M	65.1M	102.9M
Non Current Assets Total	299.6M	389.5M	520.6M	294.5M	250.9M	324.4M
Non Currrent Assets Other	2.9M	2.7M	3.0M	4.5M	(1.5M)	(1.5M)
Other Assets	39.5M	2.7M	3.0M	4.5M	4.0M	6.7M
Cash And Short Term Investments	576.9M	688.3M	353.1M	498.2M	346.4M	443.1M
Net Receivables	12.7M	10.0M	17.4M	40.1M	39.0M	20.4M
Common Stock Shares Outstanding	69.2M	131.2M	140.4M	142.5M	144.4M	131.8M
Short Term Investments	480.3M	564.8M	214.0M	408.2M	281.3M	340.3M
Liabilities And Stockholders Equity	912.3M	1.1B	923.3M	856.6M	661.1M	811.6M
Non Current Liabilities Total	263.0M	268.0M	205.4M	282.7M	264.8M	276.3M
Capital Surpluse	935.8M	1.3B	1.3B	1.4B	1.6B	910.1M
Inventory	9.1M	14.1M	19.3M	14.5M	14.4M	13.2M
Other Current Assets	14.1M	14.5M	13.0M	9.4M	10.4M	10.6M
Other Stockholder Equity	23.5M	1.3B	1.3B	1.4B	1.5B	865.0M
Total Liab	341.3M	373.1M	319.2M	392.5M	352.9M	337.9M
Net Invested Capital	571.0M	743.3M	604.0M	464.2M	308.4M	347.0M
Property Plant And Equipment Gross	60.4M	139.0M	172.9M	164.2M	193.6M	119.9M
Total Current Assets	612.7M	726.9M	402.7M	562.1M	410.2M	487.2M
Accumulated Other Comprehensive Income	671K	893K	(1.1M)	(4.1M)	215K	225.8K
Net Working Capital	534.4M	621.7M	288.9M	452.4M	322.2M	402.6M
Intangible Assets	11.9M	10.2M	8.5M	6.8M	5.1M	8.2M

Pair Trading with Adaptive Biotechnologies

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adaptive Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptive Biotechnologies will appreciate offsetting losses from the drop in the long position's value.

Moving together with Adaptive Stock

0.72	KA	Kineta Inc Financial Report 9th of May 2024	Pair Corr
0.69	ME	23Andme Holding	Pair Corr

Moving against Adaptive Stock

0.89	YS	YS Biopharma	Pair Corr
0.8	DOMH	Dominari Holdings Earnings Call This Week	Pair Corr

The ability to find closely correlated positions to Adaptive Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adaptive Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adaptive Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adaptive Biotechnologies Corp to buy it.

The correlation of Adaptive Biotechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adaptive Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adaptive Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Adaptive Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Adaptive Biotechnologies is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Adaptive Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Adaptive Biotechnologies Corp Stock. Highlighted below are key reports to facilitate an investment decision about Adaptive Biotechnologies Corp Stock:

How To Invest In Adaptive

Details

Is Adaptive Stock a good investment?

Details

What is Adaptive Biotechnologies' Net Worth?

Details

Largest Life Sciences Tools & Services Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptive Biotechnologies Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Complementary Tools for Adaptive Stock analysis

When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.

	Volatility Analysis Get historical volatility and risk analysis based on latest market data
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Global Correlations Find global opportunities by holding instruments from different markets
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.

Is Adaptive Biotechnologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adaptive Biotechnologies. If investors know Adaptive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adaptive Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.56)

Revenue Per Share

1.179

Quarterly Revenue Growth

(0.17)

Return On Assets

(0.17)

Return On Equity

(0.58)

The market value of Adaptive Biotechnologies is measured differently than its book value, which is the value of Adaptive that is recorded on the company's balance sheet. Investors also form their own opinion of Adaptive Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adaptive Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adaptive Biotechnologies' market value can be influenced by many factors that don't directly affect Adaptive Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Adaptive Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adaptive Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adaptive Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Adaptive Cash Per Share vs Price To Sales Ratio Analysis

Cash Per Share vs Price To Sales Ratio

Cash Per Share vs Price To Sales Ratio Correlation Analysis

Correlation Coefficient

Cash Per Share

Price To Sales Ratio

Adaptive Biotechnologies fundamental ratios Correlations

Adaptive Biotechnologies Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Adaptive Biotechnologies fundamental ratios Accounts

Pair Trading with Adaptive Biotechnologies

Moving together with Adaptive Stock

Moving against Adaptive Stock

Complementary Tools for Adaptive Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Capital Surpluse	+ 1.0	Common Stock Total Equity
Total Stockholder Equity	+ 0.99	Total Assets
Property Plant And Equipment Net	+ 0.99	Other Current Liab
Net Tangible Assets	+ 0.99	Total Stockholder Equity
Current Deferred Revenue	+ 0.99	Total Stockholder Equity
Good Will	+ 0.99	Long Term Debt

Non Current Liabilities Total	- 0.99	Long Term Debt Total
Non Current Liabilities Total	- 0.98	Common Stock Total Equity
Non Current Liabilities Total	- 0.98	Current Deferred Revenue
Non Current Liabilities Total	- 0.98	Net Tangible Assets
Non Current Liabilities Total	- 0.98	Total Current Liabilities
Capital Surpluse	- 0.97	Non Current Liabilities Total